TransThera Sciences (Nanjing), Inc. (HKG:2617)
Hong Kong
· Delayed Price · Currency is HKD
192.00
-2.20 (-1.13%)
At close: Dec 5, 2025
HKG:2617 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | - | - | 1.18 | 0.12 |
| Revenue Growth (YoY) | - | - | 852.42% | - |
| Gross Profit | - | - | 1.18 | 0.12 |
| Selling, General & Admin | 47.13 | 47.74 | 39.22 | 49.95 |
| Research & Development | 199.94 | 244 | 344.48 | 262.51 |
| Other Operating Expenses | 0.04 | 0.03 | 0.01 | 0.02 |
| Operating Expenses | 247.11 | 291.77 | 383.7 | 312.48 |
| Operating Income | -247.11 | -291.77 | -382.52 | -312.36 |
| Interest Expense | -0.19 | -0.2 | -0.25 | -0.18 |
| Interest & Investment Income | 1.64 | 2.17 | 12.16 | 6.02 |
| Currency Exchange Gain (Loss) | -0.8 | -0.4 | 3.01 | 27.72 |
| Other Non Operating Income (Expenses) | 2.26 | 4.91 | 10.11 | 12.57 |
| EBT Excluding Unusual Items | -244.2 | -285.29 | -357.49 | -266.24 |
| Gain (Loss) on Sale of Investments | 7.11 | 10.68 | 14.09 | 14.3 |
| Gain (Loss) on Sale of Assets | -0 | -0 | -0 | -0.01 |
| Pretax Income | -237.09 | -274.61 | -343.39 | -251.94 |
| Net Income | -237.09 | -274.61 | -343.39 | -251.94 |
| Net Income to Common | -237.09 | -274.61 | -343.39 | -251.94 |
| Shares Outstanding (Basic) | 382 | 382 | 381 | 360 |
| Shares Outstanding (Diluted) | 382 | 382 | 381 | 360 |
| Shares Change (YoY) | 0.08% | 0.06% | 5.83% | - |
| EPS (Basic) | -0.62 | -0.72 | -0.90 | -0.70 |
| EPS (Diluted) | -0.62 | -0.72 | -0.90 | -0.70 |
| Free Cash Flow | -257.08 | -271.96 | -322.81 | -238.91 |
| Free Cash Flow Per Share | -0.67 | -0.71 | -0.85 | -0.66 |
| Gross Margin | - | - | 100.00% | 100.00% |
| Operating Margin | - | - | -32389.58% | -251900.00% |
| Profit Margin | - | - | -29076.54% | -203180.65% |
| Free Cash Flow Margin | - | - | -27333.78% | -192667.74% |
| EBITDA | -244.71 | -288.85 | -378.87 | -306.29 |
| D&A For EBITDA | 2.4 | 2.92 | 3.66 | 6.07 |
| EBIT | -247.11 | -291.77 | -382.52 | -312.36 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.